Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

A real-world study found that prophylactic lanadelumab slashed hereditary angioedema (HAE) attack rates by nearly 95% in pediatric patients. Out of 13 children and adolescents treated, only one attack occurred during the entire study period. Caregivers also reported high satisfaction with the treatment, rating its effectiveness especially well.
A real-world study presented at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting shows that prophylactic lanadelumab (Takhzyro, Takeda) is highly effective at controlling hereditary angioedema (HAE) in children. Among 13 pediatric patients (ages 2–17), the monthly attack rate dropped from 0.59 at baseline to just 0.03 during treatment — a 94.9% reduction — with only a single attack occurring throughout the entire study period.
The findings build on earlier clinical trial data (the SPRING study) that led to FDA approval of lanadelumab for children aged 2 to under 12. This real-world data extends confidence in the drug's effectiveness across a broader pediatric age range and in everyday clinical settings.
By the Numbers:
Why it matters: HAE attacks can be life-threatening and severely disruptive for children and families. These real-world results reinforce that long-term prophylaxis with lanadelumab offers meaningful, sustained disease control — and that caregivers report a strongly positive treatment experience.